Boothbay Fund Management, LLC Immatics N.V. Transaction History

Boothbay Fund Management, LLC

7 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2022 Aug 15, 2022	SELL	$6.0 - $9.37 $339,042 - $529,470	-56,507 Reduced 76.36%	17,492 $152,000
Q4 2021 Feb 14, 2022	SELL	$10.81 - $14.38 $150,810 - $200,615	-13,951 Reduced 15.86%	73,999 $995,000
Q3 2021 Nov 15, 2021	BUY	$11.58 - $15.46 $755,467 - $1.01 Million	65,239 Added 287.26%	87,950 $1.14 Million
Q2 2021 Aug 16, 2021	SELL	$10.43 - $12.81 $219,113 - $269,112	-21,008 Reduced 48.05%	22,711 $264,000
Q1 2021 May 17, 2021	SELL	$10.24 - $14.6 $211,445 - $301,475	-20,649 Reduced 32.08%	43,719 $490,000
Q4 2020 Feb 12, 2021	SELL	$9.67 - $12.05 $11,313 - $14,098	-1,170 Reduced 1.79%	64,368 $695,000
Q3 2020 Nov 16, 2020	BUY	$8.73 - $15.15 $572,146 - $992,900	65,538 New	65,538 $695,000

76.6M

571K

210K

Ticker IMTX
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 76,227,000
Market Cap $894M
Description
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the discovery and development of T cell receptor (TCR) based immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as adoptive c...

Get notified when there are updates to the investment portfolio of Boothbay Fund Management, LLC, based on Form 13F filings with the SEC.

Stay updated on Boothbay Fund Management, LLC with notifications on news.